Here’s an interesting article about the use of apixaban to prevent venous thromboembolism in patients with various cancers. It came to be via the Facebook BMT and Hematological Malignancy Interest Group which up to now hasn’t been that active.
Is it perking up? Let’s hope so…
Labels: journal review
“The Oncologist” sent their most recent missive today. There was a section specifically addressing haematological stuff this time:
Labels: oncologist newsletter